Last reviewed · How we verify
Experimental: Empiric TB treatment
Empiric TB treatment is a combination regimen of multiple anti-tuberculous agents designed to target Mycobacterium tuberculosis through different mechanisms to prevent drug resistance.
Empiric TB treatment is a combination regimen of multiple anti-tuberculous agents designed to target Mycobacterium tuberculosis through different mechanisms to prevent drug resistance. Used for Tuberculosis (pulmonary and extrapulmonary).
At a glance
| Generic name | Experimental: Empiric TB treatment |
|---|---|
| Sponsor | Prof JMA Lange |
| Drug class | Anti-tuberculous agent combination |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Empiric TB treatment typically combines first-line agents such as isoniazid, rifampicin, pyrazinamide, and ethambutol, each inhibiting different aspects of mycobacterial cell wall synthesis, DNA replication, or metabolism. This multi-drug approach is standard practice to rapidly reduce bacterial burden and prevent the emergence of drug-resistant strains during the intensive phase of treatment.
Approved indications
- Tuberculosis (pulmonary and extrapulmonary)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Hyperuricemia
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: Empiric TB treatment CI brief — competitive landscape report
- Experimental: Empiric TB treatment updates RSS · CI watch RSS
- Prof JMA Lange portfolio CI